



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **Confirmation No. 8777**
Shigeru CHIKASE et al. : Attorney Docket No. 2006_0391A
Serial No. 10/574,979 : Group Art Unit 1618
Filed April 7, 2006 : Examiner Nissa M. Westerberg
AMORPHOUS ANTIBIOTIC COMPOSITION
COMPRISING CEFEDITOREN PIVOXIL : **Mail Stop AMENDMENT**

PATENT OFFICE FEE TRANSMITTAL FORM

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975

Sir:

Attached hereto is a check in the amount of \$250.00 to cover Patent Office fees relating to filing the following attached papers:

Petition for Extension of Time \$120.00


Terminal Disclaimer Fee \$130.00

A duplicate copy of this paper is being submitted for use in the Accounting Division, Office of Finance.

The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.

Respectfully submitted,

Shigeru CHIKASE et al.

By 
Amy E. Schmid
Registration No. 55,965
Attorney for Applicants

AES/emj
WENDEROTH, LIND & PONACK, L.L.P.
2033 K St., N.W., Suite 800
Washington, D.C. 20006-1021
Telephone (202) 721-8200
July 14, 2008

[Check No. 86652]
2006_0391A



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **Confirmation No. 8777**
Shigeru CHIKASE et al. : Attorney Docket No. 2006_0391A
Serial No. 10/574,979 : Group Art Unit 1618
Filed April 7, 2006 : Examiner Nissa M. Westerberg
AMORPHOUS ANTIBIOTIC COMPOSITION
COMPRISING CEFEDITOREN PIVOXIL : **Mail Stop AMENDMENT**

PATENT OFFICE FEE TRANSMITTAL FORM

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975**

Sir:

Attached hereto is a check in the amount of \$250.00 to cover Patent Office fees relating to filing the following attached papers:

Petition for Extension of Time \$120.00


Terminal Disclaimer Fee \$130.00

A duplicate copy of this paper is being submitted for use in the Accounting Division, Office of Finance.

The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.

Respectfully submitted,

Shigeru CHIKASE et al.

By 
Amy E. Schmid
Registration No. 55,965
Attorney for Applicants

AES/emj
WENDEROTH, LIND & PONACK, L.L.P.
2033 K St., N.W., Suite 800
Washington, D.C. 20006-1021
Telephone (202) 721-8200
July 14, 2008

[Check No. 86652]
2006_0391A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Shigeru CHIKASE et al.

Serial No. 10/574,979

Filed April 7, 2006



: Confirmation No. 8777

: Attorney Docket No. 2006_0391A

: Group Art Unit 1618

: Examiner Nissa M. Westerberg

AMORPHOUS ANTIBIOTIC COMPOSITION

COMPRISING CEFEDITOREN PIVOXIL

: Mail Stop: AMENDMENT

REQUEST FOR INTERVIEW

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450


THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975

Sir:

If the amendments and remarks submitted herewith are not deemed to place the application in condition for allowance, the Examiner is respectfully requested to contact the undersigned to discuss the outstanding issues. It is Applicants' opinion that the amendments and remarks set forth herein clearly establish patentability over the cited art of record. The undersigned looks forward to further communication from the Examiner.

Respectfully submitted,

Shigeru CHIKASE et al.

By: 

Amy E. Schmid
Registration No. 55,965
Attorney for Applicants

AES/emj

Washington, D.C. 20006-1021

Telephone (202) 721-8200

Facsimile (202) 721-8250

July 14, 2008